Name | Value |
---|---|
Revenues | 191.7M |
Cost of Revenue | 97.0M |
Gross Profit | 94.7M |
Operating Expense | 136.3M |
Operating I/L | -41.7M |
Other Income/Expense | 2.1M |
Interest Income | 5.3M |
Pretax | -39.5M |
Income Tax Expense | 3.2M |
Net Income/Loss | -42.7M |
Tandem Diabetes Care, Inc. is a medical device company specializing in products for insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes the t:slim X2 pump, disposable insulin cartridge, and infusion set. The company also offers t:slim X2 with Basal-IQ and control IQ technology, t:slim X2 with G5 Integration, and the Tandem Device Updater. Additionally, it provides t:connect, a web-based data management application, and Sugarmate, a mobile app for insulin users. Tandem has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories, driving its revenue through the sale of these medical devices and related technologies.